ストックスクリーナーアプリを入手
3.76
1.35%
0.05
アフターアワーズ：
3.69
-0.07
-1.86%
Evaxion A S Adr (EVAX) 最新ニュース
EVAX Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Reports No RevenueEstimate Dispersion - www.dars.gov.et
POM Stock Price, Quote & News - Syfe
Evaxion (EVAX) ADR Ticks Up to $3.08 as Micro-Cap Biotech Holds RangeInstitutional Sentiment - https://www.siam.in/
Evaxion (EVAX) ADR Ticks Up to $3.08 as Micro-Cap Biotech Holds RangeLeveraged ETF Flow - dars.gov.et
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting - GlobeNewswire Inc.
Evaxion A/S (EVAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Evaxion A/SAmerican Depositary Share (NQ: EVAX - The Chronicle-Journal
Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering - The Globe and Mail
Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering - The Globe and Mail
Evaxion (EVAX) taps investors with new ADS sale - Stock Titan
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Raises Questions on Cash BurnEarnings Sentiment Score - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentRevenue Beat Analysis - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentOperating Margin Analysis - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentGAAP Earnings Report - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentNew Analyst Coverage - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentMid-Term Outlook - dars.gov.et
Evaxion (EVAX) Levels: Posts a 0.91% Gain to $3.31 in Latest Trading; Boundary Watch: Traders Can Monitor the $3.14-$3.48 Range in the Current UpdateMcClellan Summation - dars.gov.et
Evaxion (EVAX) Levels: Posts a 0.91% Gain to $3.31 in Latest Trading; Boundary Watch: Traders Can Monitor the $3.14-$3.48 Range in the Current UpdateRisk Parity Rebalance - www.dars.gov.et
Evaxion (EVAX) Levels: Posts a 0.91% Gain to $3.31 in Latest Trading; Boundary Watch: Traders Can Monitor the $3.14-$3.48 Range in the Current UpdateGamma Flip Level - dars.gov.et
Evaxion Biotech Earnings Call: Data Strength, Cash Strain - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
EVAX Q1 2026 Earnings: Wider-than-Expected Loss of -$0.50 Per Share as Pre-Revenue Biotech Advances PipelineLow Estimate Range - careplusvn.com
Evaxion (EVAX) Steadies at $2.97 as Biotech ADS Tests Key $3.12 ResistanceInside Day Breakout - careplusvn.com
Evaxion (EVAX) Steadies at $2.97 as Biotech ADS Tests Key $3.12 ResistanceLiquidity Sweep - dars.gov.et
Evaxion (EVAX) Steadies at $2.97 as Biotech ADS Tests Key $3.12 ResistanceWatchlist Stock Ideas - dars.gov.et
Evaxion (EVAX) Holds Near $2.82 as Consolidation Range PersistsChaikin Flow - careplusvn.com
Evaxion (EVAX) Holds Near $2.82 as Consolidation Range PersistsDip Buy Trade - dars.gov.et
Evaxion (EVAX) Holds Near $2.82 as Consolidation Range PersistsDiagonal Spread Trade - dars.gov.et
Evaxion (EVAX) Edges Higher as Support Holds, Resistance LoomsTrading Ideas - dars.gov.et
Evaxion Biotech A/S Adr (EVAX) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 - GlobeNewswire Inc.
Evaxion (EVAX) Dips 1.25% as Stock Tests Support Near $3.01TICK Divergence - dars.gov.et
European ADRs Rose As Biopharma Names Led The Pack - Finimize
US-Traded European Stocks Slipped As Arm And ArcelorMittal Fell - Finimize
Evaxion A/S Sponsored ADR Actuals & Estimates (NASDAQ:EVAX) - TradingView
Evaxion receives Prix Galien UK Award for Best digital health solution - Finansavisen
European ADRs Edged Higher As Biotech Led Friday’s Moves - Finimize
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - Finansavisen
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - GlobeNewswire Inc.
European ADRs Started The Week In The Green - Finimize
European ADRs Edged Higher In US Trading - Finimize
EVAXEvaxion A/S ADR Options - Finviz
EVAX - Finviz
Evaxion Biotech Signals Strong R&D Momentum Amid Cash Constraints - TipRanks
Most VolatileStock ScreenerNews - Finviz
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer - GlobeNewswire Inc.
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer - Finansavisen
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma - GlobeNewswire Inc.
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Finansavisen
Evaxion concludes Annual General Meeting - Finansavisen
3.09%
0.72%
大文字化:
|
ボリューム (24 時間):